Magrolimab

Product NameMagrolimab
CAS2169232-81-7
MF
MW0
EINECS
MOL FileMol File

Chemical Properties

form	Liquid
color	Colorless to light yellow

Usage And Synthesis

Uses

Magrolimab (Hu5F9-G4) is a humanized anti-CD47 antibody. Magrolimab can block the "don't eat me" signal of CD47, thereby promoting macrophage mediated phagocytosis. Magrolimab has antitumor activity in malignant bone tumors and breast cancer[1][2][3].

in vivo

Magrolimab (12-100 μg; once daily; 10 days; i.p.) exhibits anti-tumor activity in mice with Ewing's sarcoma^[1]. Magrolimab (250 μg; once every two days; 7 weeks; i.p.) combined with trastuzumab (HY-P9907) can eliminate HER2 positive breast cancer cells in breast cancer mice and overcome the tolerance of trastuzumab^[2].

Animal Model:	Humanized and non-humanized ES xenograft NSG-SGM3 mice^[1].
Dosage:	12-100 μg
Administration:	Intraperitoneal injection (i.p.); once daily; 10 days
Result:	Inhibited tumor growth and lung metastasis, and prolonged animal survival time.

Animal Model:	4-8 weeks old NSG female breast cancer mouse model^[2].
Dosage:	250 μg
Administration:	Intraperitoneal injection (i.p.); once every two days; 7 weeks (implanted GFP/luciferase BT474 cells into the left mammary fat pad of female mice)
Result:	Restricted the Growth of HER2 ADCC-Tolerant Tumors.

References

[1] Luo W, et al. A humanized orthotopic mouse model for preclinical evaluation of immunotherapy in Ewing sarcoma. Front Immunol. 2023 Oct 6;14:1277987. DOI:10.3389/fimmu.2023.1277987
[2] Upton R, et al. Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance. Proc Natl Acad Sci U S A. 2021 Jul 20;118(29):e2026849118. DOI:10.1073/pnas.2026849118
[3] Liu Y, et al. PARP inhibition synergizes with CD47 blockade to promote phagocytosis by tumor-associated macrophages in homologous recombination-proficient tumors. Life Sci. 2023 Aug 1;326:121790. DOI:10.1016/j.lfs.2023.121790

Magrolimab Supplier

Magrolimab manufacturers

Related Product Information

Send Inquriy